 SAN DIEGO, May 25, 2021 GLOBE NEWSWIRE -- Fate Therapeutics, Inc. NASDAQ: FATE, a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will present at the following upcoming investor conferences: 